JavaScript is required for full functionality of this website. Please follow these simple instructions to enable JavaScript in your web browser. Please refresh this page once you have done so.

If you are still seeing this message after enabling JavaScript, please contact for further assistance.
Warning: you are accessing this website using an insecure browser. Since January 12, 2016, only the most current version of Internet Explorer available for a supported operating system receives technical support and security updates:

Our website accepts credit card payments. This requires a modern internet browser. We want to provide the best security for you and other user's financial information. On this basis, you may only access this website with the latest supported version of Internet Explorer or Microsoft Edge. Please see the most recent versions here:

As an alternative, we highly recommend using either Google Chrome or Mozilla Firefox. Both of these browsers are well known for always maintaining the highest security features.

If you are still seeing this message after installing and using one of the above browsers, please contact for further assistance.
Error: you must enable TLS 1.2 encryption to make a payment.
  1. Click the settings (Tools) icon in the top right corner.
  2. Select Internet Options
  3. Go to the Advanced tab
  4. Scroll down to the Security section
  5. Uncheck SSL 2.0 and SSL 3.0
  6. Check TLS 1.2
  7. Refresh the page
Enable TLS 1.2

If you are still seeing this message after enabling TLS 1.2, please contact for further assistance.
ICCAC [[ page.icon ]] VAD-C ™ Certification mdi-account-plus Register mdi-login Login [[ page.icon ]] [[ ]] [[ page.icon ]] VAD-C ™ Certification
Public and Regulatory Policy
Join the Public and Regulatory Policy

Chair:  Erin Davis

Chair-elect: Jennifer Nowaczyk


video about this committee


Our mission is to advocate on behalf of ICCAC by influencing international, regional, and state public policies relating to mechanical circulatory support. As a committee, we monitor legislation and regulatory agencies as they relate to MCS. These include but are not limited to, NIH, FDA, CMS, the Joint Commission, DNV, UNOS, and other international or regional regulatory bodies. Our vision is to review upcoming regulatory changes, inform our members about open comment periods, and create relevant society-level responses, approved by the ICCAC Board of Directors, to be delivered to appropriate regulatory bodies.

  • Focus on disseminating meaningful MCS 
    Policy & Regulatory content for our members (currently US only)
    • Emails
    • Social Media
    • EZ Texts
    • Timely (monthly) News Flash
  • 2 Webinars
  • Engage Transplant/MCS Financial Coordinators
  • Review and comment for CMS IPPS/OPPS billing/coding open for public comment May 2023

Join The Committee

We welcome additional members anytime who would like to join. We specifically are seeking out members with interest and knowledge of the administrative side of MCS therapy. We also do not yet have Non-US focus and will welcome that addition, if and when we have interest in that area.

Chair and Committee Member Requirements

  • At least 3 members are recommended to maintain the efficiency of the committee. There is no maximum number of members.
  • Recommend at least 1 international member, but not a requirement. Any International ICCAC member is invited to join committee calls to bring to attention international policies or regulations relating to MCS therapy
  • Recruitment is achieved through current ICCAC membership, MCS collaboration board, emails, social media, and word of mouth via colleagues
  • Chair of the committee is strictly voluntary and the individual who volunteers shall remain in the chair position for a minimum of 1 year
  • If there are no other volunteers to follow the Chair position, the individual in the chair position can maintain in this role until another volunteer is found
  • Co-Chair (if established) will take over January of the following year and will change to “Chair” status at to which time active recruitment for future co-chairs will take place
  • Minimum 1 year as MCS clinician
  • Active ICCAC Member
  • Active committee members must participate in >50% of meeting phone calls. Should schedule conflicts occur, an email including project updates will suffice.
  • Industry ICCAC members may fully participate in the committee, but may not hold the Chair or Co-Chair position

2022 Accomplishments

We are excited to have 15 members on our committee who met 3 times in 2022 and worked on the content uploaded to this website. We finalized our mission and vision of the committee and plan to provide the ICCAC membership with ongoing monitoring of the following regulatory bodies and societies:

  • CMS
  • Joint Commission
  • DNV
  • CDC / Coding Clinic
  • FDA
  • UNOS
  • MCS-related Societies: ISHLT, ASAIO, AHA, ACC, STS, HFSA, AAHFN, ESC, TFCA

Joint Commission & DNV Fall 2022 UPDATES!

The committee members worked with Joint Commission and DNV experts to compile a short reference of 2022 updates from these regulatory bodies.  Remember to always review Joint Commission and DNV information with your representative for your program's regulatory body.

European Society of Cardiology (ESC) Updates: Pulmonary Hypertension 2022

Please see below for a summary of updates provided by ESC on Pulmonary Hypertension.

MCS-related BILLING / CODING Updates

There is a new IPPS/OPPS 2023 Hospital reimbursement document live October 2022. Our committee did not find significant changes to DRG 001, 002, 003, 215, 268-270. We recommend reviewing these documents within your own program with your institution's billing/coding department.

Medicare will be decreasing physician reimbursement in 2023 with the adjusted Physician Fee Schedule (PFS) for 2023.  This has caused a lot of stir, including with cardiologists and electrophysiologists.  To learn more about this topic see Calendar Year (CY) 2023 Medicare Physician Fee Schedule Final Rule | CMS.

Society MCS-related 

HFSA: Dr. Trachtenberg, Dr. Cowger, et al. just published the 2023 HFSA Expert Consensus Statement on the Medical Management of Patients on Durable Mechanical Circulatory Support in the Journal of Cardiac Failure. Check out the full online publication by clicking the following link.

HFSA Medical Management Durable MCS

ISHLT: Dr. Bernhardt, Dr. Copeland, et al. just published the 2023 ISHLT/HFSA Guideline on Acute Mechanical Circulatory Support in the Journal of Heart and Lung Transplantation. Check out the full online publication by clicking the following link.

ISHLT Acute MCS Guidelines


The information provided by the International Consortium of Circulatory Assist Clinicians (ICCAC) is for educational purposes only.  This information should not be perceived as prescriptive or complete in its purview.  The information provided represents the opinions of the society and no one individual within the society. Please confirm with your local and governmental bodies for full and current language.  ICCAC makes no claims, promises, or guarantees about the accuracy and completeness of the included information. The information provided does not constitute legal, business, or medical advice, as such should not be wholrelied upon. You are the sole responsible party for understanding and complying with laws that apply to you and your organization. Whenever possible, ICCAC will attach available reference materials that generate the comments posted by this committee.

Committee Chairs
[[ ]] mdi-email

If you have any questions, please contact